Adial Pharmaceuticals (ADIL) Institutional Ownership $0.39 0.00 (-0.26%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Adial Pharmaceuticals (NASDAQ:ADIL)CurrentInstitutional OwnershipPercentage16.41%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$86.08KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$19.27K Get ADIL Insider Trade Alerts Want to know when executives and insiders are buying or selling Adial Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ADIL Institutional Buying and Selling by Quarter Adial Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Citadel Advisors LLC54,508$55K0.0%+63.8%0.850% 2/13/2025Renaissance Technologies LLC47,613$48K0.0%N/A0.743% 2/12/2025Geode Capital Management LLC61,847$62K0.0%+36.0%0.965% 8/9/2024Renaissance Technologies LLC34,346$39K0.0%-32.8%0.811% 5/20/2024Virtu Financial LLC20,469$27K0.0%N/A0.484% 2/13/2024Armistice Capital LLC159,000$296K0.0%N/A9.578% 11/9/2023Manchester Capital Management LLC48,097$134K0.0%-96.0%3.942% 5/9/2023Manchester Capital Management LLC1,202,452$421K0.1%N/A4.216% 11/7/2022Virtu Financial LLC77,694$27K0.0%+142.7%0.301% 8/2/2022Thompson Davis & CO. Inc.21,000$28K0.0%N/A0.088% 7/22/2022 Truist Financial Corp33,862$45K0.0%N/A0.142% 7/13/2022Private Advisor Group LLC21,400$29K0.0%-37.3%0.090% 11/12/2021 Oppenheimer & Co. Inc.38,500$165K0.0%+37.5%0.190% 11/12/2021 NorthRock Partners LLC10,000$43K0.0%N/A0.049% 10/29/2021 Commonwealth Equity Services LLC36,461$156K0.0%+25.5%0.180% 9/17/2021Virtu Financial LLC31,038$79K0.0%N/A0.153% 8/16/2021State Street Corp48,954$125K0.0%N/A0.260% 8/13/2021Northern Trust Corp21,873$56K0.0%N/A0.116% 8/13/2021Geode Capital Management LLC88,246$225K0.0%+13.2%0.469% 8/13/2021Vanguard Group Inc.585,035$1.49M0.0%+172.4%3.112% 8/11/2021 Commonwealth Equity Services LLC29,050$74K0.0%+31.7%0.155% 8/3/2021 Oppenheimer & Co. Inc.28,000$71K0.0%+93.1%0.152% 5/14/2021Dimensional Fund Advisors LP31,410$76K0.0%+68.8%0.179% (Data available from 1/1/2016 forward) ADIL Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ADIL shares? During the previous two years, the following institutional investors and hedge funds held shares of Adial Pharmaceuticals shares: Armistice Capital LLC ($296K), Manchester Capital Management LLC ($134K), Geode Capital Management LLC ($62K), Citadel Advisors LLC ($55K), and Renaissance Technologies LLC ($48K), Virtu Financial LLC ($27K).Learn more on Adial Pharmaceuticals' institutional investors. What percentage of Adial Pharmaceuticals' stock is owned by institutional investors? 16.41% of Adial Pharmaceuticals' stock is owned by institutional investors. Learn more on ADIL's institutional investor holdings. Which institutional investors have been buying Adial Pharmaceuticals' stock? The following institutional investors have purchased Adial Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($159K), Renaissance Technologies LLC ($47.61K), Citadel Advisors LLC ($21.24K), Virtu Financial LLC ($20.47K), and Geode Capital Management LLC ($16.38K). How much institutional buying is happening at Adial Pharmaceuticals? Institutional investors have bought a total of 85,232 shares in the last 24 months. This purchase volume represents approximately $86.08K in transactions. Which of Adial Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Adial Pharmaceuticals stock in the last 24 months: Renaissance Technologies LLC ($16.75K). How much institutional selling is happening at Adial Pharmaceuticals? Institutional investors have sold a total of 16,754 shares in the last 24 months. This volume of shares sold represents approximately $19.27K in transactions. Related Companies Hoth Therapeutics Major Shareholders Synlogic Major Shareholders Lexaria Bioscience Major Shareholders Lipocine Major Shareholders BioLineRx Major Shareholders Aspire Biopharma Major Shareholders Mannatech Major Shareholders Edesa Biotech Major Shareholders Abpro Major Shareholders Gelteq Major Shareholders This page (NASDAQ:ADIL) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
